4.5 Article

Human Cdc25A phosphatase has a non-redundant function in G2 phase by activating Cyclin A-dependent kinases

Journal

FEBS LETTERS
Volume 583, Issue 4, Pages 841-847

Publisher

WILEY
DOI: 10.1016/j.febslet.2009.01.044

Keywords

Cell cycle; Cdc25A; Mitosis; Cyclin A; Cyclin B/Cdk1

Funding

  1. Deutsche Krebshilfe [107058]
  2. DKFZ Guest scientist and intramural programs
  3. Gottfried Daimler und Karl Benz-Stiftung

Ask authors/readers for more resources

Cdc25 phosphatases activate Cdk/Cyclin complexes by dephosphorylation and thus promote cell cycle progression. We observed that the peak activity of Cdc25A precedes the one of Cdc25B in prophase and the maximum of Cyclin/Cdk kinase activity. Furthermore, Cdc25A activates both Cdk1-2/Cyclin A and Cdk1/Cyclin B complexes while Cdc25B seems to be involved only in activation of Cdk1/Cyclin B. Concomitantly, repression of Cdc25A led to a decrease in Cyclin A-associated kinase activity and attenuated Cdk1 activation. Our results indicate that Cdc25A acts before Cdc25B - at least in cancer cells, and has non-redundant functions in late G2/early M-phase as a major regulator of Cyclin A/kinase complexes. (C) 2009 Published by Elsevier B. V. on behalf of the Federation of European Biochemical Societies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Multidisciplinary Sciences

Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5

Fotini Vogiatzi, Dominique T. Brandt, Jean Schneikert, Jeannette Fuchs, Katharina Grikscheit, Michael Wanzel, Evangelos Pavlakis, Jol P. Charles, Oleg Timofeev, Andrea Nist, Marco Mernberger, Eva J. Kantelhardt, Udo Siebolts, Frank Bartel, Ralf Jacob, Ariane Rath, Roland Moll, Robert Grosse, Thorsten Stiewe

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

Article Biology

Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss

Onur Cizmecioglu, Jing Ni, Shaozhen Xie, Jean J. Zhao, Thomas M. Roberts

ELIFE (2016)

Article Cell Biology

Plk2 regulates centriole duplication through phosphorylation-mediated degradation of Fbxw7 (human Cdc4)

Onur Cizmecioglu, Annekatrin Krause, Ramona Bahtz, Lena Ehret, Nisar Malek, Ingrid Hoffmann

JOURNAL OF CELL SCIENCE (2012)

Article Biochemistry & Molecular Biology

Polyoma small T antigen triggers cell death via mitotic catastrophe

A. T. Pores Fernando, S. Andrabi, O. Cizmecioglu, C. Zhu, D. M. Livingston, J. M. G. Higgins, B. S. Schaffhausen, T. M. Roberts

ONCOGENE (2015)

Article Multidisciplinary Sciences

Human Cdc14B Promotes Progression through Mitosis by Dephosphorylating Cdc25 and Regulating Cdk1/Cyclin B Activity

Indra Tumurbaatar, Onur Cizmecioglu, Ingrid Hoffmann, Ingrid Grummt, Renate Voit

PLOS ONE (2011)

Article Multidisciplinary Sciences

Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases

Joel P. Charles, Jeannette Fuchs, Mirjam Hefter, Jonas B. Vischedyk, Maximilian Kleint, Fotini Vogiatzi, Jonas A. Schaefer, Andrea Nist, Oleg Timofeev, Michael Wanzel, Thorsten Stiewe

NATURE COMMUNICATIONS (2014)

Article Cell Biology

p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo

Oleg Timofeev, Katharina Schlereth, Michael Wanzel, Attila Braun, Bernhard Nieswandt, Axel Pagenstecher, Andreas Rosenwald, Hans-Peter Elsaesser, Thorsten Stiewe

CELL REPORTS (2013)

Article Biochemistry & Molecular Biology

Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses

Oleg Timofeev, Boris Klimovich, Jean Schneikert, Michael Wanzel, Evangelos Pavlakis, Julia Noll, Samet Mutlu, Sabrina Elmshaeuser, Andrea Nist, Marco Mernberger, Boris Lamp, Ulrich Wenig, Alexander Brobeil, Stefan Gattenloehner, Kernt Koehler, Thorsten Stiewe

EMBO JOURNAL (2019)

Article Cell Biology

Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo

Boris Klimovich, Thorsten Stiewe, Oleg Timofeev

CELL CYCLE (2020)

Article Multidisciplinary Sciences

Loss of p53 function at late stages of tumorigenesis confers ARF-dependent vulnerability to p53 reactivation therapy

Boris Klimovich, Samet Mutlu, Jean Schneikert, Sabrina Elmshaeuser, Maria Klimovich, Andrea Nist, Marco Mernberger, Oleg Timofeev, Thorsten Stiewe

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Article Oncology

Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and Aging

Oleg Timofeev, Lukas Koch, Constantin Niederau, Alina Tscherne, Jean Schneikert, Maria Klimovich, Sabrina Elmshaeuser, Marie Zeitlinger, Marco Mernberger, Andrea Nist, Christian Osterburg, Volker Doetsch, Martin Hrabe de Angelis, Thorsten Stiewe

CANCER RESEARCH (2020)

Article Multidisciplinary Sciences

mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability

Niklas Gremke, Pierfrancesco Polo, Aaron Dort, Jean Schneikert, Sabrina Elmshauser, Corinna Brehm, Ursula Klingmuller, Anna Schmitt, Hans Christian Reinhardt, Oleg Timofeev, Michael Wanzel, Thorsten Stiewe

NATURE COMMUNICATIONS (2020)

Review Oncology

Rely on Each Other: DNA Binding Cooperativity Shapes p53 Functions in Tumor Suppression and Cancer Therapy

Oleg Timofeev, Thorsten Stiewe

Summary: p53 is a DNA-binding protein that activates genes to suppress cancer cells, and its mutations, including cooperativity mutations, can lead to tumorigenesis. Understanding the structural basis of p53's DNA binding cooperativity is important for cancer therapy, as it plays a critical role in controlling cell fate decisions and tumor suppression. Research on p53 has provided insights into its function and potential personalized treatments for cancer patients with cooperativity mutations.

CANCERS (2021)

Article Biochemistry & Molecular Biology

p53 partial loss-of-function mutations sensitize to chemotherapy

Boris Klimovich, Nastasja Merle, Michelle Neumann, Sabrina Elmshaeuser, Andrea Nist, Marco Mernberger, Daniel Kazdal, Albrecht Stenzinger, Oleg Timofeev, Thorsten Stiewe

Summary: Partial loss-of-function mutations of p53 play a significant role in tumorigenesis, leading to mutant p53 protein accumulation similar to hotspot mutations. Unlike p53 loss, these mutations enhance apoptotic chemotherapy response and improve survival rates in a therapy context.

ONCOGENE (2022)

Article Oncology

p53 gain-of-function mutations promote metastasis via ENTPD5 upregulation and enhanced N-glycoprotein folding

Oleg Timofeev, Thorsten Stiewe

MOLECULAR & CELLULAR ONCOLOGY (2017)

No Data Available